Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Anemia is a common and disabling complication in chronic kidney disease (CKD), contributing significantly to morbidity and reduced quality of life.Desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), stimulates endogenous erythropoietin production and improves anemia. However, real-world data across diverse CKD etiologies remain limited.
This observational study included 128 Asian CKD patients (median age: 52 years; male:female ratio: 1.58:1) treated with Desidustat. CKD etiologies included CKD of uncertain cause (n=39), diabetic kidney disease (n=34), chronic glomerulonephritis (n=24), CAKUT (n=16), ADPKD (n=5), IgA nephropathy (n=5), membranous GN (n=4), myeloma kidney (n=1), and ANCA vasculitis (n=1). The majority were in advanced CKD (stage 5 ND = 77; stage 5 D = 40). Patients received Desidustat (75–450 mg/week) for 12 weeks. Hemoglobin (Hb) response was defined as an increase ≥1 g/dL or achieving >10 g/dL. Statistical analysis was performed using a paired t-test.
The study results demonstrated a progressive and sustained improvement in hemoglobin levels with Desidustat therapy among chronic kidney disease (CKD) patients over a 12-week period. The mean hemoglobin concentration increased from 7.6 g/dL at baseline to 9.6 g/dL at 12 weeks, reflecting a steady upward trend throughout the treatment period. The mean rise in hemoglobin from baseline was +0.78 g/dL at 4 weeks, +1.31 g/dL at 8 weeks, and +2.04 g/dL at 12 weeks, indicating a cumulative and clinically meaningful improvement in anemia correction with continued therapy.
When evaluated by timeline of response, the majority of patients exhibited an early and robust rise in hemoglobin: 51 patients responded within the first 0–4 weeks, 36 between 4–8 weeks, and 14 between 8–12 weeks, while 28 patients were non-responders. Thus, nearly 60% of all responders showed improvement within the first month, suggesting a rapid onset of Desidustat’s erythropoietic effect.
Response to desidustat therapy in relation to iron statusFurther subgroup analyses revealed that food intake timing and iron status did not significantly influence treatment outcomes. The response rates were comparable when Desidustat was taken before meals (20 responders, 15 non-responders) versus after meals (18 responders, 13 non-responders), with a p-value of 0.832, indicating no significant association between food timing and therapeutic response. Similarly, among patients stratified by baseline iron status, 54 iron-deplete and 35 iron-replete patients responded, while 11 iron-deplete and 11 iron-replete patients did not, yielding a p-value of 0.343, confirming that the response was independent of iron stores.
Desidustat significantly improves hemoglobin levels in CKD patients of diverse etiologies and advanced stages.The response was independent of iron status or meal timing, highlighting Desidustat’s consistency and convenience as an effective oral therapy for anemia management in real-world clinical practice.
